The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

Drugs

Volumn 60, Issue , 2000, Pages 1-14

  Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CONFERENCE PAPER; CYTOSTASIS; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; METASTASIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CLINICAL TRIALS; DRUG THERAPY; HUMANS; NEOPLASMS; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 0033762484     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060001-00001     Document Type: Article

References (64)

1. The chemotherapy of lymphomas: Looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture
2. Dose-response is alive and well
3. Testicular cancer as a model for curative neoplasms: The Richard and Hinda Rosenthal Foundation Award Lecture
4. Laboratory models: The historical perspective
5. Kinetic parameters and growth curves for experimental tumor systems
6. Growth curve of an experimental solid tumor following radiotherapy
7. The Norton-Simon Hypothesis revisited
8. A Gompertzian model of human breast cancer growth
9. A mathematical model for relating the drug sensitivities of tumors to their spontaneous mutation rate
10. Rationale for the use of alternating non-cross-resistant chemotherapy
11. Conventional cancer therapy: Promise broken or promise delayed?
12. Pharmaceutical research in molecular oncology
13. New molecular targets for Cancer Therapy
14. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities
15. The promise of molecular oncology
16. Translational research: Walking the bridge between idea and cure - Seventeenth Bruce F. Caine Memorial Award Lecture
17. Development of target-based antineoplastic agents
18. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
19. There are no bad anticancer agents, only bad clinical trial designs - Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture
20. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
21. Farnesyltransferase inhibitors: Antineoplastic mechanisms and clinical prospects
22. Blockade of receptors for growth factors: An anticancer therapy - The fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award lecture
23. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study
24. CCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule
25. Intermittent oral ZD 1839 (Iressa(TM)), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I study
26. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with five selected tumor types: Evidence of activity and good tolerability
27. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
28. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients with advanced non-small cell lung cancer
29. Comparison of potential markers of farnesyltransferase inhibition
30. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
31. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial
32. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
33. Randomized discontinuation trials: Utility and efficiency
34. Design of phase II clinical trials stopping rule using response and early progression
35. Preoperative staging of non-small cell lung cancer with positron-emission tomography
36. 2-[C-11]Thymidine imaging of malignant brain tumors
37. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients
38. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
39. Variance and sample size calculations in quality-of-life-adjusted survival analysis (Q-TWiST)
40. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma
41. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821
42. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetics in vitro
43. High affinity for FTase and alternative prenylation contribute individually to K-ras resistance to FTIs
44. Resistance of K-RasBV 12 proteins to farnesyltransferase inhibitors in Rat1 cells
45. Patient preferences for oral versus intravenous palliative chemotherapy
46. Interpatient variability in bioavailabity is related to the extent of absorption: Implications for bioavailability and bioequivalence studies
47. The effects of keoconazole on the intestinal metabolism and bioavailability of cyclosporin
48. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test
49. Patient noncompliance with self-administered chemotherapy
50. Compliance with oral drug therapy in patients with hematologic malignancy
51. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy
52. Patient compliance with oral chemotherapy as assessed by a novel oral technique
53. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
54. Interaction of the farnesyl protein transferase inhibitor R115777 with cytotoxic chemotherapeutics in vitro and in vivo
55. Enhanced efficacy of the farnesyl protein transferase inhibitor SCH66336 in combination with paclitaxel
56. The farnesyl transferase inhibitor FTI-277 radiosensitizes H-Ras transformed rat embryo fibroblasts
57. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
58. Antitumour effect of anti-epidermal growth factor mononuclear antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts
59. Epidermal growth factor receptor family and chemosensitization
60. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines
61. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
62. Potentiation of radiation-induced breast cancer cell death by inhibition of epidermal growth factor family of receptors
63. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431human squamous carcinoma cells
64. The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation